Silence Therapeutics PLC Sponsored ADR
Silence Therapeutics PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $559,000.00, down 98.7% from fiscal 2024. In the quarter to June 2026, revenue grew 197.2%, EPS grew 54.4% and free cash flow grew 107.0%, each against the same quarter a year earlier.
Follow SLN
Silence Therapeutics PLC Sponsored ADR (SLN) Altman Z-score
Silence Therapeutics PLC Sponsored ADR's Altman Z-score for fiscal 2025 is −4.82, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | −4.82 | (4.52) |
| FY2024 | −0.30 | 1.50 |
| FY2023 | −1.80 | (0.66) |
| FY2022 | −1.14 | (0.86) |
| FY2021 | −0.27 | (0.31) |
| FY2020 | 0.04 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.80 | — | 0.96 | |
| Retained earnings / total assets | (4.28) | — | −5.99 | |
| EBIT / total assets | (0.69) | — | −2.29 | |
| Market value of equity / total liabilities | 4.15 | — | 2.49 | |
| Sales / total assets | 0.00 | — | 0.00 | |
| Altman Z-score | Distress zone | −4.82 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −12.42 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| STTK Shattuck Labs, Inc. compare | 10.2× |
| SGMT Sagimet Biosciences Inc. compare | 2.5× |
| CRMD CorMedix Inc compare | 2.2× |
| DBVT DBV Technologies S.A. compare | 1.3× |
| ZVRA Zevra Therapeutics, Inc. compare | 0.6× |
| VALN Valneva SE Sponsored ADR compare | −0.5× |
| SLN Silence Therapeutics PLC Sponsored ADR | −4.8× |
| PHAT Phathom Pharmaceuticals, Inc. compare | −7.9× |
| OLMA Olema Pharmaceuticals, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets